Renassist Patient Assistance Program (RPAP)
What is RPAP?
RPAP is designed for patients in financial need who do not have coverage for Renvela® (sevelamer carbonate) (and/or Hectorol® [doxercalciferol injection]) under any prescription drug benefit, including commercial insurance, Medicare, Medicaid, or other government insurance programs.
Through a partnership with the American Kidney Fund (AKF), Sanofi provides qualifying patients with medication at no cost.
Who is eligible for assistance through RPAP?
- Patients who do not have existing drug coverage for Renvela® (sevelamer carbonate) and/or Hectorol® (doxercalciferol injection) under any prescription drug benefit, including commercial insurance, Medicare, Medicaid, or other government insurance programs
- US citizens or legal residents
- A copy of Green Card or Permanent Resident Card is required for legal residents
- Patients in the 90-day waiting period for Medicare coverage
What documentation is required?
- A Renassist® Insurance Verification Form and Patient Assistance Application (PDF) must be completed and submitted to Renassist via fax or email.
- Medicare A and B beneficiaries having household income below 150% of the Federal
Poverty Level who are applying for Renvela® (sevelamer carbonate) or Hectorol® (doxercalciferol injection) assistance must include one
of the following:
- Official notice of denial or the predecisional notice for the Low-Income Subsidy (Extra Help) from the Social Security Administration
- If applicant is a legal resident, a copy of his/her Green Card or Permanent Resident Card
What is the enrollment process?
- All applications are submitted to Renassist for review of insurance status, and then forwarded to AKF for financial review.
- The healthcare professional and/or the patient will be contacted by fax or phone if an application is incomplete or requires additional information. Please note: incomplete applications will be returned.
- AKF will send an approval or denial letter to the dialysis unit by mail or email.
- Medication will be filled by Diplomat Specialty Pharmacy in up to a 3-month supply with a maximum of 3 refills through the RPAP grant approval date for patients who continue to meet the program criteria.
Is there a need for reenrollment?
- Qualified applicants are required to reapply 1 year from the date the prescription was written.
- Should the patient or healthcare provider have questions regarding the refill process, please contact Renassist.
- T: 1-800-847-0069
- F: 1-877-363-6732
Email us at:
8:30 am to 5:00 pm EST
Indication for Renvela and Renagel
Renvela® (sevelamer carbonate) and Renagel® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
- Sevelamer is contraindicated in patients with bowel obstruction.
- Caution should be exercised in patients with dysphagia, swallowing disorders, and severe gastrointestinal (GI) motility disorders, including severe constipation or major GI tract surgery.
- Common adverse events reported with sevelamer include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation. Other events reported include pruritus, rash, fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation.
- Uncommon cases of difficulty swallowing the Renagel (sevelamer hydrochloride) or Renvela® (sevelamer carbonate) tablet have been reported. Caution should be exercised in these patients and consideration given to using Renvela® (sevelamer carbonate) suspension in patients with a history of difficulty swallowing.
- Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take sevelamer.
- Serum bicarbonate and chloride levels should be monitored.
- Follow patients for reduced vitamins D, E, and K (coagulation parameters) and folic acid levels.
- Patients should be informed to take sevelamer with meals and to adhere to their prescribed diets.
- Hectorol Injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
- Hectorol capsules are indicated for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease not on dialysis and patients with chronic kidney disease on dialysis.
Important Safety Information for Hectorol
- You should not take Hectorol if you have a history of abnormally high calcium blood levels (hypercalcemia) or if you have very high vitamin D levels.
- Overdosage of any form of vitamin D is dangerous and may require emergency attention.
- Before taking Hectorol, tell your doctor if you have ever had an irregular heartbeat or seizure, or if you are taking any digitalis drugs (or cholestyramine if you are taking Hectorol capsules).
- Serum bicarbonate and chloride levels should be monitored.
- Do not take other vitamin D related drugs if you are currently taking Hectorol.
- It is important for anyone taking Hectorol to talk to their doctor before taking any non-prescription drugs or magnesium-containing antacids, supplements and herbal preparations and to adhere to instructions about following a low phosphorus diet and calcium supplementation.
- Your doctor should monitor your calcium, phosphorus and PTH levels.
- Tell your doctor if you experience symptoms of hypercalcemia such as weakness, headache, drowsiness, nausea, vomiting, dry mouth, constipation, muscle pain, bone pain, metallic taste and loss of appetite.
- Your doctor should check and treat you for nutritional vitamin D deficiency before starting you on Hectorol capsules.
- The main side effects of treatment with Hectorol injection are hypercalcemia, hyperphosphatemia, and oversuppression of PTH. The main side effects of treatment with
- Hectorol capsules are hypercalcemia, hyperphosphatemia, hypercalciuria, and oversuppression of PTH. Your doctor may ask you questions to see if you are experiencing any symptoms related to these conditions.
- During treatment, your doctor may change your dose of Hectorol as well as the dose of your phosphate binder.
- Common side effects seen in Hectorol-treated patients on dialysis were swelling, headache, ill feeling, nausea/vomiting, dizziness, shortness of breath, itching and slow heartbeat.
- Common side effects seen in patients taking Hectorol capsules with Stage 3 or Stage 4 chronic kidney disease were infection, chest pain, constipation, indigestion, anemia, dehydration, depression, muscle stiffness, insomnia, tingling, increased cough, shortness of breath and runny/stuffy nose.
- Tell your doctor if you are pregnant or nursing.
- This drug should be used with caution if you have impaired liver function.